https://www.selleckchem.com/products/wh-4-023.html
Ruxolitinib is the most commonly used JAK-inhibitor (JAKi) for the management of symptoms related to splenomegaly and cytokine-mediated inflammation in patients with myelofibrosis (MF), but is limited by variable durability of response with most patients experiencing failure after 2-3years. Long-term data on other approved JAKi, fedratinib and pacritinib, are not available due to the clinical hold put on pivotal trials for toxicity concerns. Following the initial hold for concern of Wernicke's encephalopathy, fedratinib was approved by
Like
Comment
Share
